About
About Northeast Pharmaceutical Group Co., Ltd
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti- infective products, such as fosfomycin series, azithromycin series, amantadine series, polyalkali hydrochloride, chloramphenicol, and other products; and reproductive system and hormone products comprising carboprost suppositories, carboprost tromethamine, dapoxetine hydrochloride, and levonorgestrel and tadalafil tablets. It also provides nervous system products, such as piracetam series, levetiracetam series, vinpocetine, and other products; narcotics and psychotropic drugs and related products, including morphine hydrochloride injections and tablets, oxycodone hydrochloride injection, compound glycyrrhiza series, and acetaminophen-codeine tablets; anti-AIDS products comprising Krughar /zidovudine tablets and capsules, efavirenz tablets, and other products; and in vitro biological diagnostic reagent products for HIV, HBV, HCV, HPV, and TB. In addition, it offers general health products, including glucosamine sulfate chondroitin collagen D3 calcium capsules, protein powder, probiotic powder, effervescent tablets, chewable tablets, solid drinks, and other products. Further, it provides Enterogermina, magnesium aluminum carbonate chewable tablets; compound proglutamine-cimetidine tablets; acetaminophen tablets; pain relievers, phenacetin, pregabalin, noscapine syrup, and citrate table; and other products, as well as cell therapy products. Additionally, it engages in medical distribution business. The company was founded in 1946 and is based in Shenyang, China.
Visit company website
5 years, 5 months ago
Northeast Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 1.5% below its 200 day moving average.
From a valuation standpoint, the stock is 91.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.8.
Northeast Pharmaceutical Group Co., Ltd's total revenue sank by 12.6% to $2B since the same quarter in the previous year.
Its net income has increased by 938.9% to $11M since the same quarter in the previous year.
Finally, its free cash flow fell by 87.5% to $59M since the same quarter in the previous year.
Based on the above factors, Northeast Pharmaceutical Group Co., Ltd gets an overall score of 2/5.